Wagestream Ltd., established in 2018 and based in London, United Kingdom, offers a financial services application that empowers employees to access their earned wages on demand. This platform enables users to control their payment timing, effectively alleviating the need for advances or loans and reducing financial stress associated with unexpected expenses. Wagestream aims to combat the poverty premium and help employees avoid debt cycles linked to high-interest credit and overdraft fees. The application includes various financial tools designed to improve workplace financial well-being, allowing employees to budget, set savings goals, and manage their financial resources effectively. The company is backed by several investors, including QED, Fair by Design, London Co-Investment Fund, and Village Global.
900.care is a manufacturer of refillable bathroom products designed to promote zero-waste and reduce plastic usage. The company specializes in innovative formulations such as dissolving shower gel, chewable toothpaste, and foaming hand gel. These products not only cater to consumer needs but also prioritize environmental sustainability, allowing customers to use personal care items that are beneficial for both themselves and the planet.
Aspen Power Partners is a distributed generation platform with the dual mission of accelerating and democratizing decarbonization.
Daki is a mobile application that functions as a digital supermarket, providing customers with access to a wide range of grocery supplies and everyday necessities. The platform enables users to conveniently order products from the comfort of their homes and ensures swift delivery, often within seconds. Daki's focus on multi-category grocery offerings aims to streamline the shopping experience, making it easier for customers to meet their daily needs through a user-friendly mobile interface.
JOKR is a global last-mile delivery platform focused on providing a fast, personalized, and sustainable shopping experience for essential grocery and convenience products. By utilizing a network of micro-fulfillment centers, JOKR enables customers to receive their orders within minutes or at a scheduled time, enhancing the overall shopping experience and saving valuable time. The company emphasizes sustainability by aiming to reduce food waste and promote responsible consumption. Operating primarily in the Brazilian market under the brand "DAKI," JOKR has established a presence in major cities such as Rio de Janeiro and São Paulo. The company has attracted significant investment from notable firms, achieving a valuation of 1.3 billion dollars as of February 2023, solidifying its status as a unicorn since December 2021.
Isar Aerospace is a space technology company specializing in the development of automated production methods for rockets. The company focuses on providing launch services that facilitate the deployment and resupply of satellite constellations, aimed at offering low-cost and flexible access to space for small satellites. By prioritizing affordability and sustainability, Isar Aerospace enables clients to utilize environmentally friendly solutions for launching small payloads and upper-stage vehicles.
Le Collectionist SAS is a luxury travel brand based in Paris, France, specializing in the rental of high-end vacation properties worldwide. Established in 2012, the company provides a curated selection of exquisite villas, apartments, and luxurious houses, catering to discerning travelers seeking unique holiday experiences. In addition to offering a diverse range of properties, Le Collectionist enhances the rental experience with hotel-like services, ensuring a seamless and personalized stay. Through its marketplace platform, the company connects homeowners with tourists, enabling easy access to a variety of luxury accommodations for customized trips.
Phenix operates a waste management platform focused on reducing waste and promoting a circular economy. With a team of around 100 dedicated employees, the company aims to give a second life to both food and non-food products across various sectors, including charities. Phenix assists over 1,000 professional clients, such as retailers, manufacturers, wholesalers, shopping centers, and caterers, in managing their unsold products and waste. The platform offers an alternative to landfills and incineration, enabling clients to efficiently manage their inventories and donate surplus items to charitable organizations. Through its comprehensive collaborative and logistical services, Phenix encourages businesses to actively participate in waste reduction efforts and enhance their corporate social responsibility initiatives.
Pearlx Infrastructure is specialized in digitally connecting global infrastructure assets and offers energy leasing position.
Everdrop GmbH, founded in 2019 and based in Munich, Germany, specializes in the production of sustainable cleaning products aimed at minimizing plastic waste. The company manufactures plastic-free packaged cleanser tablets, which can be mixed at home, along with reusable spray bottles and laundry detergent powder. Everdrop's product line also includes vegan natural cosmetics, all designed to eliminate single-use plastics and unnecessary chemicals. By offering these eco-friendly solutions, Everdrop enables consumers to maintain a clean household in a straightforward and sustainable way.
Isar Aerospace is a space technology company specializing in the development of automated production methods for rockets. The company focuses on providing launch services that facilitate the deployment and resupply of satellite constellations, aimed at offering low-cost and flexible access to space for small satellites. By prioritizing affordability and sustainability, Isar Aerospace enables clients to utilize environmentally friendly solutions for launching small payloads and upper-stage vehicles.
Taurus SA is a Swiss FinTech company founded in April 2018 that specializes in providing a comprehensive digital asset infrastructure for financial institutions. The platform enables the issuance, custody, and trading of various digital assets, including cryptocurrencies, tokenized assets, and non-fungible tokens (NFTs). Taurus serves a diverse clientele, including systemic banks, universal banks, online banks, crypto-banks, private banks, and broker-dealers, establishing itself as a leader in the banking sector. Additionally, Taurus operates a marketplace for private assets and tokenized securities. As a supervised and regulated securities firm under FINMA, Taurus ensures compliance and security in managing digital assets.
TriArm Therapeutics is a cell therapy company established by Panacea Venture, with research and development operations in Germany, the United States, and the Greater China region. The company specializes in the research and clinical development of CD19 CAR-T products, utilizing non-viral gene transfer technology. This innovative approach significantly lowers both the cost and preparation time associated with cell therapy products, ultimately aiming to enhance therapeutic outcomes for cancer patients.
PrimaryBid Limited operates an online investment platform that provides private investors with access to capital raising opportunities from AIM-listed companies. Founded in 2012 and based in London, the platform allows investors to bid for new shares on their own terms, ensuring they transact simultaneously and at the same price as institutional investors. PrimaryBid facilitates participation in placings, fundraisings, and IPOs, thereby democratizing access to investment opportunities. The company has established strategic partnerships with firms such as Shore Capital Group, finnCap, and Arden, enhancing its reach and infrastructure. Through a long-term agreement with the London Stock Exchange, PrimaryBid connects retail investors with public companies, enabling seamless transactions during critical fundraising moments.
Simba Sleep is a London-based company that specializes in designing and manufacturing mattresses, pillows, duvets, bedding, and bed bases. Founded in 2015, the company combines innovative materials such as precision-engineered foam and patented conical pocket springs to create a range of mattresses that promote comfortable sleep. Simba Sleep emphasizes the importance of quality rest in daily life, aiming to help customers improve their sleep experience. Its products are available for purchase online and in select retail locations, including John Lewis stores in the United Kingdom. Additionally, Simba Sleep offers financing options for customers looking to invest in better sleep.
PrimaryBid Limited operates an online investment platform that provides private investors with access to capital raising opportunities from AIM-listed companies. Founded in 2012 and based in London, the platform allows investors to bid for new shares on their own terms, ensuring they transact simultaneously and at the same price as institutional investors. PrimaryBid facilitates participation in placings, fundraisings, and IPOs, thereby democratizing access to investment opportunities. The company has established strategic partnerships with firms such as Shore Capital Group, finnCap, and Arden, enhancing its reach and infrastructure. Through a long-term agreement with the London Stock Exchange, PrimaryBid connects retail investors with public companies, enabling seamless transactions during critical fundraising moments.
Attraqt is a technology company that develops and provides e-commerce solutions focused on site search, merchandising, and product recommendations. Based in London, it serves a diverse range of sectors including fashion, homeware, health and beauty, and electronics, among others. The company offers a cloud-based Software as a Service platform that enhances e-commerce performance through API-enabled, intelligent services. These solutions enable retailers to create personalized shopping experiences by optimizing product discovery and facilitating seamless customer journeys. Attraqt's platform incorporates AI capabilities, allowing clients to implement real-time personalization strategies and integrate their own algorithms. With a presence in multiple international markets, Attraqt supports over 300 leading brands and retailers in achieving their commercial objectives while enhancing customer engagement.
Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of anticalin-based drugs. Anticalins are engineered proteins derived from naturally occurring lipocalins, which have the ability to bind and transport a variety of molecules. The company's clinical pipeline includes PRS-060, a drug candidate in Phase I trials for asthma and inflammatory diseases, and PRS-343, a bispecific protein also in Phase I trials for oncology. Additionally, Pieris is advancing PRS-344, a bispecific anticalin-antibody fusion protein in preclinical development, and PRS-080, which targets hepcidin for treating iron deficiency in patients with chronic kidney disease, currently in Phase IIa trials. Pieris has established strategic partnerships with several organizations, including Les Laboratoires Servier and AstraZeneca, and engages in research collaborations with academic institutions such as the University of Pittsburgh. The company was incorporated in 2000 and aims to address high unmet medical needs across various therapeutic areas, including cancer and severe asthma.
Agensys a biotechnology company, engages in the research and development of therapeutic human monoclonal antibodies and antibody drug conjugates for the treatment of cancer. It offers products to treat various tumors, as well as prostate, pancreatic, and bladder cancers. The company, formerly known as UroGenesys, was founded in 1997 and is based in Santa Monica, California. As of December 18, 2007, Agensys, Inc. operates as a subsidiary of Astellas Pharma US, Inc.
Palatin Technologies is a biopharmaceutical company focused on developing targeted, receptor-specific peptide therapeutics to address significant unmet medical needs. Based in Cranbury, New Jersey, the company’s lead product is Vyleesi, a melanocortin receptor agonist designed for the treatment of premenopausal women with hypoactive sexual desire disorder. Palatin is also advancing several other candidates, including oral PL8177, which targets inflammatory bowel diseases, and systemic PL8177, aimed at treating non-infectious uveitis and COVID-19. Additionally, the company is developing PL9643 for anti-inflammatory ocular conditions like dry eye disease, as well as PL3994 and PL5028, which target cardiovascular and fibrotic diseases. Their research emphasizes the modulation of melanocortin and natriuretic peptide receptor systems to resolve inflammation and facilitate tissue healing, with applications extending to various conditions, including obesity, erectile dysfunction, and pulmonary diseases.
Agensys a biotechnology company, engages in the research and development of therapeutic human monoclonal antibodies and antibody drug conjugates for the treatment of cancer. It offers products to treat various tumors, as well as prostate, pancreatic, and bladder cancers. The company, formerly known as UroGenesys, was founded in 1997 and is based in Santa Monica, California. As of December 18, 2007, Agensys, Inc. operates as a subsidiary of Astellas Pharma US, Inc.
AGY Therapeutics has one focus: the discovery, development and commercialization of breakthrough treatments for diseases of the central nervous system AGY has a pipeline of novel CNS therapeutic programs in the clinic and in preclinical development to meet major unmet medical needs. AGY built its pipeline using its unique, proprietary platform for functional gene discovery and mapping out specific pathways underlying central nervous system diseases. By harnessing these capabilities, AGY identified potential target proteins that can be modulated to block the progression of the disease process. This is paving the way for novel CNS therapeutics and future growth for AGY.
Fast Track: a completely new and comprehensive approach to the way clinical trials are managed. The company is assembling a creative and energetic staff of technical and medical professionals, an experienced management team, industry-specific advisory boards, and an active investor constituency - all aggressively focused on achieving their vision: to revolutionize the management of clinical trials.
Kuros Biosciences AG is a Swiss biopharmaceutical company dedicated to developing innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has created a diverse pipeline leveraging proprietary technologies. The company specializes in biopharmaceutical products aimed at treating chronic diseases, focusing on sealants and orthobiologics. Its sealant product, Neuroseal, is under review for CE marking in the EU, while its orthobiologics offerings include MagnetOs Granules and MagnetOs Putty, approved for orthopedic and dental use in both the EU and the US. Kuros also has advanced clinical programs, with products like KUR-111 and KUR-113 having completed Phase II trials for bone fractures. Collaborations, such as with Checkmate Pharmaceuticals, further enhance its oncology treatment development. With its operational base in Schlieren, Switzerland, Kuros is transitioning to a commercial stage, aiming for broader market reach in key therapeutic areas.
Agensys a biotechnology company, engages in the research and development of therapeutic human monoclonal antibodies and antibody drug conjugates for the treatment of cancer. It offers products to treat various tumors, as well as prostate, pancreatic, and bladder cancers. The company, formerly known as UroGenesys, was founded in 1997 and is based in Santa Monica, California. As of December 18, 2007, Agensys, Inc. operates as a subsidiary of Astellas Pharma US, Inc.
Ceptyr, Inc was founded to focus on developing drugs against protein tyrosine phosphatases (PTPs), a largely unexplored niche in pharmaceutical development.